Ricinine|CAS 524-40-3|DC Chemicals

Cas No.:	524-40-3
Chemical Name:	Ricinine
Synonyms:	3-Pyridinecarbonitrile,1,2-dihydro-4-methoxy-1-methyl-2-oxo-;Ricinine;4-methoxy-1-methyl-2-oxopyridine-3-carbonitrile;Ricinine solution;4-Methoxy-1-methyl-2-oxo-1,2-dihydro-pyridin-3-carbonitril;4-methoxy-1-methyl-2-oxo-1,2-dihydro-pyridine-3-carbonitrile;Recinine;Recinine Ricidine Ricinin Ritsinin;Ricidine;Ricinin;Ritsinin;BPBio1_000853;NCGC00142397-01;4-methoxy-1-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile;130UFS7AE0;Prestwick3_000678;3-Pyridinecarbonitrile,2-dihydro-4-methoxy-1-methyl-2-oxo-;CS-0083725;NCGC00016487-03;NSC409913;NCGC00016487-02;HMS2097G17;NCGC00169517-02;5-22-07-00318 (Beilstein Handbook Reference);NCGC00169517-01;1,2-dihydro-4-methoxy-1-methyl-2-oxo-3-pyridimecarbonitrile;NSC-642604;BRD-K82561139-001-05-0;CHEMBL1329957;FT-0674423;Ricinine-(methyl-d3);Prestwick2_000678;CHEBI:18043;HY-121944;SPBio_002696;SCHEMBL257955;3-Pyridinecarbonitrile, 1,2-dihydro-4-methoxy-1-methyl-2-oxo-;E88580;Nicotinonitrile, 1,2-dihydro-4-methoxy-1-methyl-2-oxo-;4-methoxy-1-methyl-2-oxo-pyridine-3-carbonitrile;1,2-Dihydro-4-methoxy-1-methyl-2-oxo-3-pyridinecarbonitrile;CCG-36061;MFCD00171320;NCGC00016487-04;Prestwick1_000678;ACon1_001266;CAS-524-40-3;NCGC00016487-05;EINECS 208-359-7;4-methoxy-1-methyl-2-oxohydropyridine-3-carbonitrile;NS00015447;NSC-409913;Prestwick_1041;NCGC00016487-01;4-Methoxy-1-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile;TNP00192;1,2-Dihydro-1-methyl-4-methoxy-2-oxo-3-pyridine carbonitrile;524-40-3;Q907865;HMS1570G17;PETSAYFQSGAEQY-UHFFFAOYSA-N;MEGxp0_000747;NSC642604;BRD-K82561139-001-01-9;1,2-Dihydro-4-methoxy-1-methyl-2-oxo-Nicotinonitrile;FS-7365;Ricinine, >=95% (LC/MS-ELSD);BRN 0139222;WLN: T6NVJ A1 CCN DO1;UNII-130UFS7AE0;RICININE [MI];RICININE;SMR000386989;FT-0632288;NSC 409913;BSPBio_000775;HMS1539K09;HMS2268G21;NSC 642604;AKOS003673683;C01526;1,2-Dihydro-4-methoxy-1-methyl-2-oxonicotinonitrile;Nicotinonitrile,2-dihydro-4-methoxy-1-methyl-2-oxo-;TimTec1_001989;Prestwick0_000678;DTXSID50200412;MLS001048969;SY256804;Oprea1_847597;ricinine;MLSMR;STL564798;DTXCID50122903;3-cyano-4-methoxy-n-methyl-2-pyridone;DB-052124;3-Pyridinecarbonitrile, 1,2-dihydro-4-methoxy-1-methyl-2-oxo-(9CI)
SMILES:	CN1C=CC(=C(C#N)C1=O)OC
Formula:	C₈H₈N₂O₂
M.Wt:	164.16132
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.